HerediGENE is a test that fully analyzes a panel of 52 genes, including BRCA1 and BRCA2, which are associated with increased risk of developing breast, ovarian and other hereditary cancers.
prime DX is a cancer molecular test that incorporates a 1021 tumor-related multi-gene panel associated with the patient's response on targeted therapies, PARP inhibitors and chemotherapy.
The prime DX new technology for tumor molecular profiling is compatible with both FFPE and PLASMA.
Mo.Re. (Molecular Response) is a multi-gene assay developed to provide an insight to the tumor’s biology of each patient.
Personalized pharmacotherapy based on human DNA.
are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze the genes associated with inherited cardiovascular disease.
are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze genes associated with hereditary neurological and developmental disorders.
Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.
Microsatellite Instability (MSI) is a condition that appears on the DNA of specific cells (such as cancer cells) where the number of microsatellites (short repeats of DNA sequences) in these cells, is different from the repeats that existed in the DNA when it was inherited.
The PD-L1 test helps doctors determine whether a patient is likely to benefit from cancer drugs known as immune checkpoint inhibitors.
PCA3 is a non-invasive test for the detection of prostate cancer, highly specific and more precise than all other available screening tests for prostate cancer and is performed on a simple urine sample.
In Genekor, we offer Single Gene analysis with the highest quality, using the most advanced technology available.
The MyWes gene test analyzes more than 20,000 genes associated with inherited diseases, helping the doctor diagnose diseases with unclear phenotypes and antenatal care.
Genekor is a Molecular Biology Laboratory, focused in Oncology, Cardiology, Neurology and Pharmacogenetics. Our journey began in 2007 and we constantly grow in order to provide the highest quality services in the Molecular Medicine sector. A passionate team sharing the same vision on quality healthcare and molecular science is working together in order to provide patients and physicians with reliable actionable information.
Genekor’s highly experienced scientific and management team are cooperating passionately in order to provide the physicians and patients with the highest quality services in Oncology, Cardiology, Neurology and Pharmacogenetics.
See Genekor' s publications and posters.
According to a new Italian scientific study published in the Journal of Thoracic Oncology of the International Association for the Study of Lung Cancer, patients with lung cancer who quit smoking after being diagnosed with the disease have a significant improvement in survival 29% compared to those who continue to smoke despite being diagnosed.
According to a new Italian scientific study published in the Journal of Thoracic Oncology of the International Association for the Study of Lung Cancer, patients with lung cancer who quit smoking after being diagnosed with the disease have a significant improvement in survival 29% compared to those who continue to smoke despite being diagnosed.
Twenty-one articles published between 1980 and 2021 were included, which encompassed a total of over 10,000 Lung Cancer patients. There was substantial variability across studies in terms of design, patients’ characteristics, treatments received, criteria used to define smoking status (quitters or continued), and duration of follow-up.
The researchers concluded that quitting smoking at or around diagnosis is associated with a beneficial effect on the survival of Lung Cacncer patients. Treating physicians should educate LC patients about the benefits of quitting smoking even after diagnosis and provide them with the necessary smoking cessation support.
Source: https://www.jto.org/article/S1556-0864(21)03404-3/fulltext
01.02.2022